AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Red Cell Partners Appoints Michael Kilberry as Chief Product and Technology Officer
ByAinvest
Wednesday, Jul 16, 2025 9:04 am ET1min read
Red Cell Partners has appointed Michael Kilberry as its new chief product and technology officer. Kilberry brings extensive experience in the finance industry, previously working at Bloomberg. His appointment is expected to strengthen Red Cell's product and technology capabilities.
Red Cell Partners, a prominent incubation and investment firm specializing in rapidly scalable technology-led companies, has appointed Michael Kilberry as its new Chief Product and Technology Officer. Kilberry, a seasoned executive with extensive experience in the technology sector, brings a wealth of expertise that is expected to significantly bolster Red Cell's product and technology capabilities.Kilberry, who previously held senior roles at Google and Amazon, will be responsible for shaping and executing the product and technology vision across Red Cell's ecosystem. He will identify market opportunities, define product and technical strategies, and work closely with teams across Red Cell’s incubations to guide the development and delivery of innovative, mission-driven technologies. Kilberry's appointment follows his successful tenure at Google Cloud, where he served as Head of Product for AI/ML, Data & Analytics. Before joining Google, he founded and led an applied AI startup in the legal industry and held senior leadership roles at Microsoft and Snowflake [1].
Red Cell Partners, which focuses on healthcare, cyber, and national security, aims to develop powerful tools and technologies to address pressing national challenges. With Kilberry's leadership, the company hopes to accelerate its product development and technology initiatives, positioning itself to respond effectively to the rapidly evolving market demands. Kilberry's appointment underscores Red Cell's commitment to leveraging cutting-edge technology to drive innovation and improve patient outcomes [2].
References:
[1] https://finance.yahoo.com/news/michael-kilberry-former-google-amazon-120000390.html
[2] https://www.terumo.com/newsrelease/detail/20250711/6656
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet